Fig. 6. YYDRxG motif can potentially serve as a biomarker of broad neutralization against SARS-CoV-2 VOCs.
a YYDRxG antibodies sequenced from COVID-19 and vaccinated individuals. The number of YYDRxG antibody sequences identified in each individual’s antibodies (Seq. identified) were split into three groups according to the medical history reported in their original publication33–35,38,39,42. All antibody sequences (n = 17,536) sequenced from COVID-19 patients without vaccination (n = 4), COVID-19 patients vaccinated post-recovery (n = 6), and vaccinees without COVID-19 history (n = 22) are included in this analysis. Non-parameter Kruskal-Wallis test was used to compare the number of YYDRxG antibodies isolated in each group. N.S., not significant (P > 0.05). Sequence counts for each individual are included in Supplementary Table 3. b Representative antibodies with only sequence information available show potent neutralization. MOD8_P2_IgG_B11-P1369 and PZF12_P2_IgG_F7-P1369, were selected from 72 sequences, which do not have any neutralization data available (Supplementary Table 2). The two antibodies were cloned, expressed, purified, and tested against SARS-CoV-2, VOCs and SARS-CoV in a pseudovirus neutralization assay. Error bars indicate standard deviation (SD) of at least two biological replicates. Neutralization potency, i.e., IC50s, are shown between the two panels.